Double-Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression

Wilde, J. De; Mertens, C; Dorpe, J. Van; Bruhwyler, Jacques; Géczy, Joseph

doi:10.1002/(sici)1099-1077(199701/02)12:1<41::aid-hup829>3.0.co;2-7

Cited by 9 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the treatment results in the two groups showed no difference in any of the rating methods used (HDRS, HARS and MADRS). These results tend to corroborate those obtained (21) and mianserin (27). They also corroborate the recognized antidepressant efficacy of moclobemide (1,(10)(11)(12)(13)(14).…”

Section: Discussionsupporting

confidence: 90%

“…Pirlindole is a tetracyclic compound that has been characterized as a potential antidepressant drug in preclinical studies (16)(17)(18), and in which interest has been shown due to its marked selectivity as a RIMA (19). In clinical trials, the efficacy and safety of pirlindole have been demonstrated compared to placebo (20) and to reference standard drugs such as maprotiline (21), imipramine (22, 23), amitriptyline (23)(24)(25), desipramine (26) and mianserin (27).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Tanghe¹,

Geerts²,

Dorpe³

et al. 1997

Acta Psychiatr Scand

Self Cite

View full text Add to dashboard Cite

The aim of this double-blind randomized study was to compare the efficacy and the tolerability of moclobemide (300-600 mg daily) and pirlindole (150-300 mg daily), two reversible inhibitors of MAO-A (RIMAs), in the treatment of depression. In total 116 patients were included in the trial, 111 patients (52 patients on pirlindole and 59 patients on moclobemide) were evaluable for efficacy and safety, and 77 patients completed the whole study (42 days of administration). Both treatments produced highly significant improvements in the Hamilton Depression Rating Scale (HDRS) score, the Hamilton Anxiety Rating Scale (HARS) score and the Montgomery-Asberg Rating Scale (MADRS) score from day 7 to day 42. The pattern of development of the three scores in the two groups did not differ significantly. After 42 days of treatment, an improvement of > or = 50% in the HDRS score was noted in 80% and 67% of patients in the pirlindole and moclobemide groups, respectively. A total of 30 (58%) patients on pirlindole and 33 (56%) patients on moclobemide experienced side-effects that were considered to be possibly or probably related to the medication. The differences between the two drugs were non-significant for all types of side-effect, with the exception of dry mouth and tachycardia, which were significantly more frequent with moclobemide.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Tanghe¹,

Geerts²,

Dorpe³

et al. 1997

Acta Psychiatr Scand

Self Cite

View full text Add to dashboard Cite

show abstract

Effective resolution of racemic pirlindole at the preparative scale

Tullio

Ceccato

Liégeois³

et al. 1999

Chirality

View full text Add to dashboard Cite

First Preparative Enantiomer Resolution of Pirlindole, a Potent Antidepressant Drug

Tullio

Felikidis

Pirotte

et al. 1998

Helvetica Chimica Acta

View full text Add to dashboard Cite

Pirlindole is an antidepressant drug. It acts principally as reversible inhibitor of monoamine oxidase‐A (RIMA) and appears relatively potent in comparison with reference drugs. Pirlindole possesses stereogenic center but is generally used as racemate. In this work, the first preparative resolution of its enantiomeric couple is described. Whereas selective crystallization of salts of chiral acid failed, two asymmetric synthetic pathways were also examined; however, without success. Finally separation and isolation of enantiomers of pirlindole was completed by using the derivatization method coupled with preparative HPLC. Optical purity of each isomer was determined by chiral HPLC. The specific rotation of each antipode was also determined.

show abstract

Double-Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression

Cited by 9 publications

References 11 publications

Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Effective resolution of racemic pirlindole at the preparative scale

First Preparative Enantiomer Resolution of Pirlindole, a Potent Antidepressant Drug

Contact Info

Product

Resources

About